Get Our Top Trade Ideas Delivered Daily - 65% Off Now
get this deal
España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Our Top Trade Ideas Delivered Daily - 65% Off Now
get this deal
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Alzheimer's
Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks
Cassava Sciences Cooperates With DOJ, SEC On Controversial Alzheimer's Drug Investigation
Alzheimer's Drug Trial Results Questioned After 'Damning' FDA Inspection Report
Cassava Sciences Cooperates With DOJ, SEC On Controversial Alzheimer's Drug Investigation
Alzheimer's Drug Trial Results Questioned After 'Damning' FDA Inspection Report
Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others
FDA Approves Biogen's Alzheimer's Drug: Here Are Other Companies With Treatments In The Pipeline
Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others
FDA Approves Biogen's Alzheimer's Drug: Here Are Other Companies With Treatments In The Pipeline
Tesla, Amazon, Microsoft, Cassava Sciences, Intuitive Surgical: Why These 5 Stocks Are Drawing Investors' Attention Today
Psychedelics For Alzheimer's And Stress-Induced Disorders Under Study At Columbia University
Read More...
Alzheimer's Recent News
Nasdaq Futures Slip But S&P 500, Dow Futures Hold Up Ahead Of Market Open — Apple, Biogen Stocks In Focus
U.S. stocks could struggle for direction on Wednesday after the market struggled en route to a mixed close in the previous session. Volatility could be the order of the day as another batch of Fed speeches are in the pipeline.
Why Biogen Stock Is Up 40% Today
Biogen, Inc. (NASDAQ: BIIB) shares are soaring over 43% to their highest level in about a year in premarket trading Wednesday.
Benzinga's Daily Brief On Trending Tickers For April 19, 2022: Plug Power, Twitter, Cassava Sciences And More
Benzinga’s “Daily Brief On Trending Tickers” features top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items possibly impacting those stocks.
IGC THC-Drug For Alzheimer's Symptoms Proved Safe & Effective, Pending FDA Approval For More Trials
India Globalization Capital, Inc.
FDA Narrows Label To Recommend Use Of Biogen's Aduhelm In Mild Alzheimer's Patients
Biogen Inc. (NASDAQ: BIIB) shares are lower after the company announced an updated label for its recently-approved Alzheimer's treatment Adu
Biogen Gets FDA Nod For Controversial Alzheimer's Drug; First Treatment Approval For The Disease In 18 Years
After months of wait, Biogen Inc. (NASDAQ: BIIB) has finally achieved success by taking its controversial Alzheimer's treatment past the finish line.
Biogen Surges Higher On Favorable FDA Briefing Doc For Alzheimer's Candidate
Biogen Inc (NASDAQ: BIIB) shares were soaring Wednesday in reaction to an FDA briefing document released ahead of Friday's Adcom meeting on the investigational Alzheimer's drug aducanumab, an amyloid beta-targeting antibody.
Biogen Soars As FDA Accepts Alzheimer's Drug For Review In 'Next Stage Of Aducanumab Saga'
Biogen Inc's (NASDAQ: BIIB) investigational Alzheimer's drug aducanumab — a drug for which the company halted studies at one point last year — could finally see the light of day.
Biogen Delays Regulatory Filing For Approval Of Alzheimer's Drug, Shares Slump
Biogen Inc (NASDAQ: BIIB) shares were under pressure Wednesday following the release of the biotech's first-quarter report, including the statement that Biogen's BLA filing for its Alzheimer's drug will be delayed.
VTV Therapeutics 'Close To The Finish Line' On What FDA, Diabetes Patients Want: An Adjunct Therapy To Insulin
Biogen's Alzheimer's Drug Has 'Decent Shot' At FDA Approval, Analyst Says
Neurotrope Rips 150% Higher On Improved Alzheimer's Data, NIH Funding
Biogen Analysts Divided Over Alzheimer's Drug Following CTAD Presentation
Biogen's CTAD Presentation On Aducanumab Elicits Mixed Response
Chinese Regulators Tentatively Approve Novel Alzheimer's Drug — The First Since 2003
Cramer Makes The Case Why Biogen's Stock Could Double In Value
Biogen Plans Filing For Failed Alzheimer's Drug After New Analysis; Shares Hit 7-Month High
Why Neurotrope Is Plunging On Heavy Volume
Novartis, Amgen Scrap Pivotal Study Of Alzheimer's Prevention Drug
Biogen Plunges 25% After Company Discontinues Alzheimer's Drug Study
Alzheon's IPO: What You Need To Know
Adam Feuerstein Cautious On Biogen Following Alzheimer's Study
Neurotrope Alzheimer's Candidate Could Generate Revenue Beginning In 2024, Analyst Says